In an interim analysis of this phase 3 trial, the addition of pembrolizumab to chemotherapy resulted in longer progression-free survival than chemotherapy alone among patients with advanced ...
Immune checkpoints are regulators of the immune system. The interaction between PD-L1 (red molecule) on the surface of a cancer cell (red) and the immune checkpoint PD-1 (blue molecule) on a T-cell ...
In the 11 years since it was approved for the treatment of melanoma, pembrolizumab (Keytruda) has become the go-to for adjuvant or neoadjuvant therapy for advanced melanoma, despite the potential for ...
This study adds to the body of evidence pertaining to the role of immune checkpoint blockade in HCC.* *Relevance section written by JCO Associate Editor Eileen M. O'Reilly, MD. Eligible patients were ...
Outcomes for Children With Type II and Type III Pleuropulmonary Blastoma Following Chemotherapy: A Report From the International PPB/DICER1 Registry The median study follow-up was 45.0 months ...
Triple-negative breast cancer is an aggressive breast cancer subtype, and there remains an unmet need to improve outcomes in patients with previously untreated, programmed death ligand 1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results